WHO’s Access Roadmap And The Art Of Accommodation Of Pharma Interest 26/01/2019 by Intellectual Property Watch 1 Comment The Roadmap to access to medicines, vaccines and other health products (Roadmap) to be discussed at this week’s 144th session of WHO’s Executive Board accommodates vital interest of pharmaceutical TNCs on critical issues such as the approach to access, technical assistance on the use of TRIPS flexibilities and access to biosimilars. Adoption of the Roadmap in its current form very well accommodates the interest of the Pharmaceutical TNCs and therefore one need not expect any proactive steps by WHO towards promoting access after the adoption of the Roadmap.
WHO Director Tedros: Innovation, Digital Health A Major Pillar In WHO Transformation 24/01/2019 by William New, Intellectual Property Watch 1 Comment The World Health Organization is significantly upgrading its focus on digital health and innovation as it moves into a new era, renovating literally every aspect of the organisation, the WHO director general told member states today.
India, Ecuador, Peru Bring TRIPS Flexibilities Into WHO Universal Health Coverage Discussions 24/01/2019 by Catherine Saez, Intellectual Property Watch 1 Comment Universal health coverage is a goal shared by all members of the World Health Organization. The ways to achieve that goal might however be based on different strategies. As members are working on a common resolution for the approval of the Executive Board of the organisation, and are contributing draft text, India brought up the intellectual property dimension by suggesting the text includes mention of the use of international trade rules flexibilities to protect public health.
WHO Cancer Report Stirs Debate On Eve Of Board Meeting 23/01/2019 by William New, Intellectual Property Watch 3 Comments As the World Health Organization Executive Board gathers tomorrow for its annual January meeting, health industry and advocacy groups have seized on a WHO report to be presented to the Board that finds high prices for cancer medicines are “impairing” governments’ ability to provide affordable treatments. One issue they may have in common is a desire for more transparency in analyses of prices.
Special Report: Guide To This Week’s WHO Board Meeting – Budget, Medicines Access, Antimicrobial Resistance, NCDs, More 18/01/2019 by Catherine Saez, Intellectual Property Watch 1 Comment The World Health Organization Executive Board this month will consider an 8 percent WHO budget increase for 2020-2021, discuss environment health risks, the high price of cancer drugs, and how to facilitate access to medicines and vaccines. Also on the agenda is the fight against antimicrobial resistance, rising noncommunicable diseases, and tuberculosis. In another area, the Board is also expected to discuss its pandemic influenza framework, in particular access to influenza viruses under the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity. The Board will further be asked to consider new entities seeking to enter into official relationships with the WHO, and those with whom relations should be discontinued.
Supporting UHC And Better Explaining IP – The 2019 Pharma Industry Agenda 16/01/2019 by Intellectual Property Watch 1 Comment In 2019, IFPMA work will continue to focus on constructive engagement in supporting UHC and working with others to strengthen health care systems. The association will continue to engage with a range of stakeholders, particularly multilateral organizations, to better explain the benefits of IP and exchange ideas to address issues of coverage, capacity, affordability and sustainability of healthcare.
WHO Report Shows Global Progress On Influenza Preparedness Response 18/12/2018 by David Branigan, Intellectual Property Watch Leave a Comment The World Health Organization has released a new report showing that significant progress has been made to build national and global preparedness for future influenza pandemics. This progress resulted from the collaborative multi-sectoral implementation of a WHO plan, funded by the benefit-sharing contributions of industry partners, to strengthen global health security against pandemic influenza.
WHO To Form Expert Panel On Challenges Of Human Gene Editing 17/12/2018 by Intellectual Property Watch 1 Comment The World Health Organization has announced it will be establishing a global multidisciplinary panel of experts “to examine the scientific, ethical, social and legal challenges associated with human gene editing.”
Experts Call For Global Accountability Mechanism For Access To Essential Medicines 10/12/2018 by Intellectual Property Watch 1 Comment Global health experts, including senior officials at the World Health Organization, are calling for a global accountability mechanism for access to essential medicines, noting that a the lack of data on medicines affordability and national pharmaceutical expenditures has hindered this process, according a recent article published in UK medical journal The Lancet.
Transparency Of Patent Status Key For Health Actors: Databases Presented At WIPO 05/12/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment Information on the status of patents can be key for medicines procurement agencies seeking to know if they can source cheaper generic products. Several databases providing free information on patent status were presented yesterday at the World Intellectual Property Organization. The World Health Organization, also invited, hailed the efforts, but warned against listing follow-on patents, which could confuse procurement professionals. And a prominent molecular biologist, chief executive of a patents-and-scholarly database, called for breaking silos to advance innovation.